-
1.发明授权Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents 有权螺 - 羟吲哚化合物的对映异构体及其用作治疗剂公开(公告)号：US09480677B2
公开(公告)日：2016-11-01
申请号：US14510634
申请日：2014-10-09
IPC分类号： A61K31/407 , C07D491/22 , C07D491/20
CPC分类号： C07D491/20 , A61K31/407 , C07B57/00 , C07B2200/07 , C07D491/22
摘要： This invention is directed to the (S)-enantiomer of the compound of formula (I): or a pharmaceutically acceptable solvate or prodrug thereof. This (S)-enantiomer is useful for the treatment of diseases or conditions, such as pain, which are ameliorated or alleviated by the modulation of voltage-gated sodium channels.
摘要翻译： 本发明涉及式（I）化合物的（S） - 对映异构体的制备方法：该（S） - 对映体可用于治疗疾病或病症如疼痛，其被改善或缓解 通过电压门控钠通道的调制。
-
公开(公告)号：US09260446B2
公开(公告)日：2016-02-16
申请号：US14272297
申请日：2014-05-07
发明人： Jean-Jacques Alexandre Cadieux , Mikhail Chafeev , Sultan Chowdhury , Jianmin Fu , Qi Ji , Stefanie Abel , Emad El-Sayed , Elke Huthmann , Thomas Isarno
IPC分类号： C07D491/20
CPC分类号： C07D491/20 , C07D405/04
摘要： This invention is directed to methods of preparing certain spiro-oxindole derivatives, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
-
公开(公告)号：US20200030260A1
公开(公告)日：2020-01-30
申请号：US16523568
申请日：2019-07-26
发明人： Robin Paul Sherrington , Jean-Jacques Alexandre Cadieux , Parisa Karimi Tari , Jeffrey Paul Bechard
IPC分类号： A61K31/137 , A61K31/24 , A61P25/08
摘要： In certain embodiments, the present disclosure is directed to methods and uses for treating a mammal having an epileptic seizure disorder or being at risk for having an epileptic seizure disorder, comprising administering certain herein disclosed isolated fenfluramine enantiomers that are surprisingly effective as anti-epilepsy drugs (AEDs), despite having lower anti-seizure potency than fenfluramine racemate, by virtue of also being less cardiotoxic than fenfluramine racemate. Preferred embodiments contemplate treatment of Dravet syndrome; other preferred embodiments contemplate treatment of other epileptic seizure disorders.
-
公开(公告)号：US20160326184A1
公开(公告)日：2016-11-10
申请号：US14989600
申请日：2016-01-06
发明人： Jean-Jacques Alexandre Cadieux , Mikhail Chafeev , Sultan Chowdhury , Jianmin FU , Qi Jia , Stefanie Abel , Emad El-Sayed , Elke Huthmann , Thomas Isarno
IPC分类号： C07D491/20 , C07D405/04
CPC分类号： C07D491/20 , C07D405/04
摘要： This invention is directed to methods of preparing certain spiro-oxindole derivatives, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
-
5.发明申请ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS 有权螺旋体化合物的使用者及其作为治疗剂的用途公开(公告)号：US20150025121A1
公开(公告)日：2015-01-22
申请号：US14510634
申请日：2014-10-09
IPC分类号： A61K31/407 , C07D491/20
CPC分类号： C07D491/20 , A61K31/407 , C07B57/00 , C07B2200/07 , C07D491/22
摘要： This invention is directed to the (S)-enantiomer of the compound of formula (I): or a pharmaceutically acceptable solvate or prodrug thereof. This (S)-enantiomer is useful for the treatment of diseases or conditions, such as pain, which are ameliorated or alleviated by the modulation of voltage-gated sodium channels.
摘要翻译： 本发明涉及式（I）化合物的（S） - 对映异构体：或其药学上可接受的溶剂合物或前药。 该（S） - 对映体可用于治疗通过调节电压门控钠通道而改善或缓解的疾病或病症，例如疼痛。
-
公开(公告)号：US20210169839A1
公开(公告)日：2021-06-10
申请号：US17109937
申请日：2020-12-02
摘要： Disclosed herein are immediate-release oral pharmaceutical formulations comprising a therapeutically effective amount of ezogabine and one or more pharmaceutically acceptable excipients for use in treating epilepsy and/or epileptic seizure disorders in a mammal, preferably a human, more preferably a child. Also disclosed are methods of using and making the immediate-release oral pharmaceutical formulations.
-
公开(公告)号：US20150291623A1
公开(公告)日：2015-10-15
申请号：US14542367
申请日：2014-11-14
发明人： Mikhail Chafeev , Sultan Chowdhury , Lauren Fraser , Jianmin Fu , Jonathan Langille , Shifeng Liu , Jianyu Sun , Shaoyi Sun , Serguei Sviridov , Mark Wood , Alla Yurevna Zenova , Qi Jia , Jean-Jacques Alexandre Cadieux , Simon J. Gauthier , Amy Frances Douglas , Tom Hsieh , Nagasree Chakka , Zoran Cikojevic
IPC分类号： C07D513/20 , C07D519/00 , C07D491/22 , C07D491/20 , C07D498/20
CPC分类号： C07D513/22 , C07D491/10 , C07D491/107 , C07D491/20 , C07D491/22 , C07D495/20 , C07D498/20 , C07D513/20 , C07D519/00
摘要： This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
摘要翻译： 本发明涉及螺 - 羟吲哚化合物，作为立体异构体，对映体，其互变异构体或其混合物; 或其药学上可接受的盐，溶剂合物或前药用于治疗和/或预防钠通道介导的疾病或病症，例如疼痛。
-
公开(公告)号：US20140336390A1
公开(公告)日：2014-11-13
申请号：US14272297
申请日：2014-05-07
发明人： Jean-Jacques Alexandre Cadieux , Mikhail Chafeev , Sultan Chowdhury , Jianmin Fu , Qi Ji , Stefanie Abel , Emad El-Sayed , Elke Huthmann , Thomas Isarno
IPC分类号： C07D491/20
CPC分类号： C07D491/20 , C07D405/04
摘要： This invention is directed to methods of preparing certain spiro-oxindole derivatives, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
摘要翻译： 本发明涉及制备某些螺 - 羟吲哚衍生物的方法，其可用于治疗和/或预防钠通道介导的疾病或病症如疼痛。
-
公开(公告)号：US20240279182A1
公开(公告)日：2024-08-22
申请号：US18540582
申请日：2023-12-14
IPC分类号： C07D217/04
CPC分类号： C07D217/04 , C07B2200/13
摘要： The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.
-
10.发明公开公开(公告)号：US20230404913A1
公开(公告)日：2023-12-21
申请号：US18248661
申请日：2021-04-09
IPC分类号： A61K9/00 , A61K9/16 , A61K9/20 , A61K9/10 , A61K9/28 , A61K31/635 , A23L33/00 , A23L33/125
CPC分类号： A61K9/0053 , A61K9/1623 , A61K9/1652 , A61K9/1617 , A61K9/2054 , A61K9/2013 , A61K9/10 , A61K9/2866 , A61K31/635 , A23L33/40 , A23L33/125
摘要： Provided herein are certain pharmaceutical compositions comprising (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-yl)benzene-sulfonamide (Compound A), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient. The pharmaceutical compositions can be present in form of an immediate release tablet, a granular formulation, a stable suspension oral dosage form or a multi-particulate sprinkle dosage form. Methods for the treatment of a disease or a condition associated with Naj4.6 activity, such as epilepsy, are described.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.031 秒)
